Department of Diagnostic and Molecular Imaging, Interventional Radiology, Nuclear Medicine and Radiation Therapy, University of Rome Tor Vergata, Viale Oxford 81, 00133, Rome, Italy.
Support Care Cancer. 2011 Jul;19(7):957-62. doi: 10.1007/s00520-010-0910-1. Epub 2010 May 27.
The aim of our study was to assess the efficacy and safety of percutaneous osteoplasty (PO), a technical extension of percutaneous vertebroplasty, in the treatment of extraspinal bone lesions from multiple myeloma causing pain resistant to NSAID therapy or treated with opioids.
Between March 2006 and January 2009, 39 patients (22 female), median age 64 years (range 48-88 years) with diagnosis of multiple myeloma, were treated with percutaneous osteoplasty for painful extraspinal bone lesions resistant to NSAID therapy or treated with opioids.
Technical success was achieved in all cases. Mean visual analog pain score (VAS) scores dropped from 8.4 ± 1 (range 6-10; pretreatment) to 2.1 ± 1.7 (range 0-7; 24-h posttreatment). Pain completely disappeared in six (15%) patients. Administration of analgesics was suspended in 16 (41%) patients whereas in 17 (43.5%) patients previously treated with opioids, residual pain was controlled by NSAIDs. In six (15%) patients, narcotics administration was continued due to the persistence of pain. All patients completed an at least 6-month follow-up with a median long-term VAS score of 2.4 ± 2.1 (range 0-9). In five (13%) patients, pain remission was complete, with no recurrence at 18 months from treatment.
Our study suggests that PO may be feasible, effective, and safe in the treatment of conventional therapy-resistant extraspinal painful multiple myeloma lesions providing long-lasting pain relief with occasional tumor control and a significant reduction in the assumption of analgesic drugs.
本研究旨在评估经皮骨成形术(PO)的疗效和安全性,PO 是经皮椎体成形术的技术延伸,用于治疗对非甾体抗炎药(NSAID)治疗抵抗或使用阿片类药物治疗的多发性骨髓瘤引起的脊柱外骨病变导致的疼痛。
2006 年 3 月至 2009 年 1 月,39 例(22 名女性)诊断为多发性骨髓瘤的患者,中位年龄 64 岁(范围 48-88 岁),采用经皮骨成形术治疗对 NSAID 治疗抵抗或使用阿片类药物治疗的脊柱外骨病变引起的疼痛。
所有病例均达到技术成功。平均视觉模拟疼痛评分(VAS)从 8.4±1(范围 6-10;治疗前)降至 2.1±1.7(范围 0-7;治疗后 24 小时)。6 例(15%)患者疼痛完全消失。16 例(41%)患者停止使用镇痛药,而 17 例(43.5%)先前使用阿片类药物治疗的患者则通过 NSAIDs 控制残留疼痛。6 例(15%)患者因疼痛持续而继续使用阿片类药物。所有患者均完成至少 6 个月的随访,中位长期 VAS 评分为 2.4±2.1(范围 0-9)。5 例(13%)患者疼痛完全缓解,治疗后 18 个月无复发。
我们的研究表明,PO 可能是一种可行、有效且安全的治疗方法,可用于治疗常规治疗抵抗的脊柱外疼痛性多发性骨髓瘤病变,提供持久的疼痛缓解,偶尔可控制肿瘤,并显著减少镇痛药的使用。